人膀胱移行细胞癌细胞T24
BLUEFBIO™ Product Sheet
|
细胞名称 |
人膀胱移行细胞癌细胞T24 |
|
|
|
货物编码 |
BFN608006696 |
||
|
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
|
细胞数量 |
1x10^6 |
1x10^6 |
|
|
保存温度 |
37℃ |
-198℃ |
|
|
运输方式 |
常温保温运输 |
干冰运输 |
|
|
安全等级 |
1 |
||
|
用途限制 |
仅供科研 1类 |
||
|
培养体系 |
DMEM高糖培养基+10%FBS+1%双抗 |
||
|
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
|
简介 |
人膀胱移行细胞癌细胞T24取自82岁女性供体。 |
||
|
注释 |
Part of: BLA-40 bladder carcinoma cell line panel. Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: MD Anderson Cell Lines Project. Part of: UBC-40 urothelial bladder cancer cell line index. Doubling time: 19 hours (PubMed=4133950); 21 hours (PubMed=3708594); 23.2 hours (PubMed=26055179); ~48 hours (DSMZ); ~1 day (lot 02052018) (JCRB). Microsatellite instability: Stable (MSS) (Sanger). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep quantitative proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Exosome proteome analysis. Omics: GPI-anchored proteins analysis by proteomics. Omics: Protein expression by reverse-phase protein arrays. Omics: Proteome analysis by 2D-DE/MS. Omics: SNP array analysis. Omics: Transcriptome analysis. |
||
|
STR信息 |
Amelogenin X CSF1PO 10,12 (ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=11416159; PubMed=27270441; TKG) 12 (RCB) D1S1656 12,15 D2S1338 20,23 D3S1358 16 (CCRID; KCLB) 16,21 (CLS) D5S818 10,12 (ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=11416159; PubMed=27270441; TKG) 10 (RCB) D6S1043 11 D7S820 10,11 D8S1179 9,14 (CLS) 14 (CCRID; PubMed=11416159) D12S391 17,18 D13S317 12 (ATCC; CCRID; CLS; Cosmic-CLP; JCRB; KCLB; PubMed=27270441; RCB; TKG) 9,12 (DSMZ) D16S539 9 D18S51 16,18 D19S433 13,14 D21S11 29 FGA 17,22 Penta D 11,15 Penta E 7,10 TH01 6 TPOX 8,11 vWA 17 (ATCC; CCRID; Cosmic-CLP; JCRB; RCB; TKG) 17,19 (CLS; DSMZ; KCLB; PubMed=11416159; PubMed=27270441) |
||
|
参考文献 |
PubMed=29732388; DOI=10.3233/BLC-180167 Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D. Systematic review: characteristics and preclinical uses of bladder cancer cell lines. Bladder Cancer 4:169-183(2018)
CLPUB00543 Min Q., Cao S.-N., Gan Y.-P., Song T.-S., Liu F.-X., Ning Z.-F. Bladder cancer chemotherapy resistant cell harbors stem-like characteristics construction and characterization of T24 resistance strain of bladder cancer. Clin. Oncol. J. 1:1004.09-1004.12(2019)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)
PubMed=31978347; DOI=10.1016/j.cell.2019.12.023 Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180:387-402(2020) |
||
